Review of the international consensus guidelines for the optimal use of the polymyxins

Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(4):282-309

​ Eliseeva E.V., Azyzov I.S., Zubareva N.A.
10.36488/cmac.2019.4.282-309
polymyxins colistin polymyxin B guidelines
Section
Antimicrobials
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(4):282-309

Abstract

Polymyxins are often the only agents that remain in vitro active against extensively resistant bacterial pathogens. However, the use of polymyxins is compromised by the number of unresolved issues, including the technical aspects of antimicrobial susceptibility testing, pharmacokinetic and pharmacodynamics parameters, optimal dosing regimens, and combined use with other antibiotics. All of the aspects of polymyxin use are discussed in detail in recently published «International consensus guidelines for the optimal use of the polymyxins», that was endorsed by the following professional societies: American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antiinfective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Ekaterina V. Eliseeva

Pacific State Medical University, Vladivostok, Russia

Azyzov Ilya Sulejmanovich

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Zubareva N.A.

Perm State Medical University named after E.A. Wagner, Perm, Russia

  • 1. Li J., Nation R.L., Turnidge J.D., Milne R.W., Coulthard K., Rayner C.R., et al. Colistin: the re-emerging antibiotic for multidrugresistant gram-negative bacterial infections. Lancet Infect Dis. 2006;9:589-601. DOI: 10.1016/S1473-3099(06)70580-1
  • 2. Lim L.M., Ly N., Anderson D., Yang J.C., Macander L., Jarkowski A. 3rd, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;12:1279-1291. DOI: 10.1592/phco.30.12.1279
  • 3. Nation R.L., Li J., Turnidge J.D. The urgent need for clear and accurate information on the polymyxins. Clin Infect Dis. 2013;11:1656-1657. DOI: 10.1093/cid/cit522
  • 4. Nation R.L., Li J., Cars O., Couet W., Dudley M.N., Kaye K.S., et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015;2:225-234. DOI: 10.1016/S1473-3099(14)70850-3
  • 5. Onufrak N.J., Rao G.G., Forrest A., Pogue J.M., Scheetz M.H., Nation R.L., et al. Critical need for clarity in polymyxin B dosing. Antimicrob Agents Chemother. 2017;61(5). pii:e00208-17. DOI: 10.1128/AAC.00208-17
  • 6. Nation R.L., Garonzik S.M., Thamlikitkul V., GiamarellosBourboulis E.J., Forrest A., Paterson D.L., et al. Dosing guidance for intravenous colistin in critically ill patients. Clin Infect Dis. 2017;5:565-571. DOI: 10.1093/cid/ciw839
  • 7. Pogue J.M., Ortwine J.K., Kaye K.S. Optimal usage of colistin: are we any closer? Clin Infect Dis. 2015;12:1778-1780. DOI: 10.1093/cid/civ723
  • 8. Zavascki A.P., Nation R.L. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? Antimicrob Agents Chemother. 2017;61(3). pii:e02319-16. DOI: 10.1128/AAC.02319-16
  • 9. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;7650:924-926. DOI: 10.1136/bmj.39489.470347.AD
  • 10. ISO. Clinical laboratory testing and in vitro diagnostic test systems – susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices – Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. ISO 20776-1:2006.
  • 11. EUCAST. Recommendations for MIC determination of Colistin (polymyxin E) as recommended by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group. EUCAST, 2016. Available at: www.eucast.org/ast_of_bacteria/guidance_documents/. Accessed January 24, 2019.
  • 12. CLSI. Available at: https://clsi.org/media/1700/clsi-newswinter-2016.pdf. Accessed January 24, 2019.
  • 13. Hindler J.A., Humphries R.M. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant gramnegative bacilli. J Clin Microbiol. 2013;51(6):1678-1684. DOI: 10.1128/JCM.03385-12.14
  • 14. CLSI. M100-S27. Performance Standards for Antimicrobial Susceptibility Testing: 26th Informational Supplement. Wayne, PA: CLSI; 2017.
  • 15. EUCAST. European Committee on Antimicrobial Susceptibility Testing breakpoint tables for interpretation of MICs and zone diameters. Version 7.1. 2017. Available at: www.eucast.org/clinical_breakpoints/. Accessed January 24, 2019.
  • 16. Liu Y.Y., Wang Y., Walsh T.R., Yi L.X., Zhang R., Spencer J., et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;2:161168. DOI: 10.1016/S1473-3099(15)00424-7
  • 17. Mediavilla J.R., Patrawalla A., Chen L., Chavda K.D., Mathema B., Vinnard C., et al. Colistin- and carbapenem-resistant Escherichia coli harboring mcr-1 and blaNDM-5, causing a complicated urinary tract infection in a patient from the United States. MBio. 2016;7(4). pii::e01191-16. DOI: 10.1128/mBio.01191-16
  • 18. McGann P., Snesrud E., Maybank R., Corey B., Ong A.C., Clifford R., et al. Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first report of mcr-1 in the United States. Antimicrob Agents Chemother. 2016;7:4420-4421. DOI: 10.1128/AAC.01103-16
  • 19. Li J., Rayner C.R., Nation R.L., Owen R.J., Spelman D., Tan K.E., et al. Heteroresistance to Colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2006;9:2946-2950. DOI: 10.1128/AAC.00103-06
  • 20. Tsuji B.T., Landersdorfer C.B., Lenhard J.R., Cheah S.E., Thamlikitkul V., Rao G.G., et al. Paradoxical effect of polymyxin B: high drug exposure amplifies resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;7:3913-3920. DOI: 10.1128/AAC.02831-15
  • 21. Tam V.H., Schilling A.N., Vo G., Kabbara S., Kwa A.L., Wiederhold N.P., et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;9:3624-3630. DOI: 10.1128/AAC.49.9.36243630.2005
  • 22. Bergen P.J., Li J., Nation R.L., Turnidge J.D., Coulthard K., Milne R.W. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother. 2008;3:636642. DOI: 10.1093/jac/dkm511
  • 23. Ly N.S., Yang J., Bulitta J.B., Tsuji B.T. Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;6:3453-3456. DOI: 10.1128/AAC.06380-11
  • 24. Bulman Z.P., Satlin M.J., Chen L., Kreiswirth B.N., Shin B.S., Walsh T.J., et al. New polymyxin B dosing strategies to fortify old allies in the war against KPC-2-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61(4). pii: e02023-16. DOI: 10.1128/AAC.02023-16
  • 25. Deris Z.Z., Yu H.H., Davis K., Soon R.L., Jacob J., Ku C.K., et al. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2012;10:5103-5112. DOI: 10.1128/AAC.01064-12
  • 26. Bergen P.J., Bulitta J.B., Forrest A., Tsuji B.T., Li J., Nation R.L. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother. 2010;9:3783-3789. DOI: 10.1128/AAC.00903-09
  • 27. Khan D.D., Friberg L.E., Nielsen E.I. A pharmacokineticpharmacodynamic (PK/PD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin. J Antimicrob Chemother. 2016;7:1881-1884. DOI: 10.1093/jac/dkw057
  • 28. Hengzhuang W., Wu H., Ciofu O., Song Z., Høiby N. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother. 2012;56(5):2683-2690. DOI: 10.1128/AAC.06486-11
  • 29. Cheah S.E., Wang J., Nguyen V.T., Turnidge J.D., Li J., Nation R.L. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother. 2015;12:3291-3297. DOI: 10.1093/jac/dkv267
  • 30. Landersdorfer C.B., Wang J., Wirth V., Chen K., Kaye K.S., Tsuji B.T. Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. J Antimicrob Chemother. 2018;73(2):462-468. DOI: 10.1093/jac/dkx409
  • 31. Sader H.S., Rhomberg P.R., Farrell D.J., Jones R.N. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. Diagn Microbiol Infect Dis. 2015;4:379-381. DOI: 10.1016/j.diagmicrobio.2015.08.013
  • 32. Nation R.L., Garonzik S.M., Li J., Thamlikitkul V., GiamarellosBourboulis E.J., Paterson D.L., et al. Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis. 2016;5:552-558. DOI: 10.1093/cid/civ964
  • 33. Garonzik S.M., Li J., Thamlikitkul V., Paterson D.L., Shoham S., Jacob J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;7:3284-3294. DOI: 10.1128/AAC.01733-10
  • 34. Sorli L., Luque S., Grau S., Berenguer N., Segura C., Montero M.M., et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13:380. DOI: 10.1186/14712334-13-380
  • 35. Forrest A., Garonzik S.M., Thamlikitkul V., Giamarellos-Bourboulis E.J., Paterson D.L., Li J., et al. Pharmacokinetic/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients. Antimicrob Agents Chemother. 2017;61(11). pii:e01367-17. DOI: 10.1128/AAC.01367-17
  • 36. Horcajada J.P., Sorli L., Luque S., Benito N., Segura C., Campillo N., et al. Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate. Int J Antimicrob Agents. 2016;6:725-727. DOI: 10.1016/j.ijantimicag.2016.08.020
  • 37. Mouton J.W., Muller A.E., Canton R., Giske C., Kahlmeter G., Turnidge J. MIC-based dose adjustment: facts and fables. J Antimicrob Chemother. 2018;73(3):564-568. DOI: 10.1093/jac/dkx427
  • 38. Forrest A., Silveira F.P., Thamlikitkul V., et al. Toxicodynamics for colistin-associated changes in creatinine clearance. Interscience Conference on Antimicrobial Agents and Chemotherapy 2014, Washington, DC, 2014.
  • 39. Lakota E.A., Landersdorfer C.B., Nation R.L., Li J., Kaye K.S., Rao G.G., et al. Personalizing polymyxin B dosing using an adaptive feedback control algorithm. Antimicrob Agents Chemother. 2018;62(7):e00483-18. DOI: 10.1128/AAC.00483-18
  • 40. Bulitta J.B., Yang J.C., Yohonn L., Ly N.S., Brown S.V., D'Hondt R.E., et al. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother. 2010;5:2051-2062. DOI: 10.1128/AAC.00881-09
  • 41. Ly N.S., Bulman Z.P., Bulitta J.B., Baron C., Rao G.G., Holden P.N., et al. Optimization of polymyxin B in combination with doripenem to combat mutator Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;5:2870-2880. DOI: 10.1128/AAC.02377-15
  • 42. Kwa A., Kasiakou S.K., Tam V.H., Falagas M.E. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007;5:811-821. DOI: 10.1586/14787210.5.5.811
  • 43. Nation R.L., Velkov T., Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59:88-94. DOI: 10.1093/cid/ciu213
  • 44. Sandri A.M., Landersdorfer C.B., Jacob J., Boniatti M.M., Dalarosa M.G., Falci D.R., et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524531. DOI: 10.1093/cid/cit334
  • 45. Thamlikitkul V., Dubrovskaya Y., Manchandani P., Ngamprasertchai T., Boonyasiri A., Babic J.T., et al. Dosing and pharmacokinetics of polymyxin B in patients with renal insufficiency. Antimicrob Agents Chemother. 2016;61(1). pii: e01337-16. DOI: 10.1128/AAC.01337-16
  • 46. Zavascki A.P., Goldani L.Z., Cao G., Superti S.V., Lutz L., Barth A.L., et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008;10:1298-1304. DOI: 10.1086/592577
  • 47. Kwa A.L., Abdelraouf K., Low J.G., Tam V.H. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis. 2011;10:1280-1281. DOI: 10.1093/cid/cir137
  • 48. Oliveira M.S., Prado G.V., Costa S.F., Grinbaum R.S., Levin A.S. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis. 2009;4:431-434. DOI: 10.1016/j.diagmicrobio.2009.07.018
  • 49. Akajagbor D.S., Wilson S.L., Shere-Wolfe K.D., Dakum P., Charurat M.E., Gilliam B.L. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis. 2013;9:1300-1303. DOI: 10.1093/cid/cit453
  • 50. Phe K., Lee Y., McDaneld P.M., Prasad N., Yin T., Figueroa D.A., et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014;5:2740-2746. DOI: 10.1128/AAC.02476-13
  • 51. Tuon F.F., Rigatto M.H., Lopes C.K., Kamei L.K., Rocha J.L., Zavascki A.P. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014;4:349-352. DOI: 10.1016/j.ijantimicag.2013.12.002
  • 52. Rigatto M.H., Oliveira M.S., Perdigao-Neto L.V., Levin A.S., Carrilho C.M., Tanita M.T., et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother. 2016;4:24432449. DOI: 10.1128/AAC.02634-15
  • 53. Vardakas K.Z., Falagas M.E. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;2:233-238. DOI: 10.1016/j.ijantimicag.2016.07.023
  • 54. Crass R.L., Rutter W.C., Burgess D.R., Martin C.A., Burgess D.S. Nephrotoxicity in patients with or without cystic fibrosis treated with polymyxin B compared to colistin. Antimicrob Agents Chemother. 2017;61(4). pii:e02329-16. DOI: 10.1128/AAC.02329-16
  • 55. Couet W., Gregoire N., Gobin P., Saulnier P.J., Frasca D., Marchand S., et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther. 2011;6:875-879. DOI: 10.1038/clpt.2011.48
  • 56. Luque S., Escano C., Sorli L., Li J., Campillo N., Horcajada J.P., et al. Urinary concentrations of colistimethate and formed colistin after intravenous administration in patients with multidrugresistant Gram-negative bacterial infections. Antimicrob Agents Chemother. 2017;61(8). pii:e02595-16. DOI: 10.1128/AAC.02595-16
  • 57. European Medicines Agency. Assessment report on polymyxinbased products. Referral under Article 31 of Directive 2001/83/EC. Available at: www.ema.europa.eu/documents/referral/polymyxin-article-31-referral-assessment-report_en.pdf. Accessed January 24, 2019.
  • 58. Nation R.L., Li J., Cars O., Couet W., Dudley M.N., Kaye K.S., et al. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis. 2014;1:139-141. DOI: 10.1093/cid/cit680
  • 59. Plachouras D., Karvanen M., Friberg L.E., Papadomichelakis E., Antoniadou A., Tsangaris I., et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;8:3430-3436. DOI: 10.1128/AAC.01361-08
  • 60. Mohamed A.F., Karaiskos I., Plachouras D., Karvanen M., Pontikis K., Jansson B., et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;8:4241-4249. DOI: 10.1128/AAC.06426-11
  • 61. Karaiskos I., Friberg L.E., Pontikis K., Ioannidis K., Tsagkari V., Galani L., et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients. Antimicrob Agents Chemother. 2015;12:7240-7248.
  • 62. Gregoire N., Mimoz O., Megarbane B., Comets E., Chatelier D., Lasocki S., et al. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob Agents Chemother. 2014;58(12):73247330. DOI: 10.1128/AAC.03508-14
  • 63. He H., Li J.C., Nation R.L., Chen G., Lee H.J., Tsuji B.T., et al. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J Antimicrob Chemother. 2013;10:23112317. DOI: 10.1093/jac/dkt207
  • 64. Shields R.K., Anand R., Clarke L.G., Paronish J.A., Weirich M., Perone H., et al. Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria. PLoS One. 2017;3:e0173286. DOI: 10.1371/journal.pone.0173286
  • 65. Kumar A., Roberts D., Wood K.E., Light B., Parrillo J.E., Sharma S., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;6:1589-1596. DOI: 10.1097/01.CCM.0000217961.75225.E9
  • 66. Luna C.M., Aruj P., Niederman M.S., Garzón J., Violi D., Prignoni A., et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J. 2006;1:158164. DOI: 10.1183/09031936.06.00049105
  • 67. Kumar A., Ellis P., Arabi Y., Roberts D., Light B., Parrillo J.E., et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;5:1237-1248. DOI: 10.1378/chest.09-0087
  • 68. EUCAST. European Committee on Antimicrobial Susceptibility Testing. MIC distributions and ECOFFs. Available at: www.eucast.org/mic_distributions_and_ecoffs/. Accessed January 24, 2019.
  • 69. Pogue J.M., Ortwine J.K., Kaye K.S. Clinical considerations for optimal use of the polymyxins: a focus on agent selection and dosing. Clin Microbiol Infect. 2017;4:229-233. DOI: 10.1016/j.cmi.2017.02.023
  • 70. Marchand S., Frat J.P., Petitpas F., Lemaître F., Gobin P., Robert R., et al. Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother. 2010;8:18361837. DOI: 10.1093/jac/dkq185
  • 71. Markou N., Fousteri M., Markantonis S.L., Zidianakis B., Hroni D., Boutzouka E., et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother. 2012;10:24592462. DOI: 10.1093/jac/dks257
  • 72. Karvanen M., Plachouras D., Friberg L.E., Paramythiotou E., Papadomichelakis E., Karaiskos I., et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother. 2013;1:668-671. DOI: 10.1128/AAC.00985-12
  • 73. Luque S., Sorli L., Li J., Collado S., Barbosa F., Berenguer N., et al. Effective removal of Colistin methanesulphonate and formed colistin during intermittent haemodialysis in a patient infected by polymyxin-only-susceptible Pseudomonas aeruginosa. J Chemother. 2014;2:122-124. DOI: 10.1179/1973947813Y.0000000104
  • 74. Mariano F., Leporati M., Carignano P., Stella M., Vincenti M., Biancone L. Efficient removal of colistin A and B in critically ill patients undergoing CVVHDF and sorbent technologies. J Nephrol. 2015;5:623-631. DOI: 10.1007/s40620-0140143-3
  • 75. Jacobs M., Gregoire N., Megarbane B., Gobin P., Balayn D., Marchand S., et al. Population pharmacokinetics of colistin methanesulphonate (CMS) and colistin in critically ill patients with acute renal failure requiring intermittent haemodialysis. Antimicrob Agents Chemother. 2016;60(3):1788-1793. DOI: 10.1128/AAC.01868-15
  • 76. Karaiskos I., Friberg L.E., Galani L., Ioannidis K., Katsouda E., Athanassa Z., et al. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents. 2016;3:337-341. DOI: 10.1016/j.ijantimicag.2016.06.008
  • 77. Strunk A.K., Schmidt J.J., Baroke E., Bode-Böger S.M., MartensLobenhoffer J., Welte T., et al. Single- and multiple-dose pharmacokinetics and total removal of colistin in a patient with acute kidney injury undergoing extended daily dialysis. J Antimicrob Chemother. 2014;7:2008-2010. DOI: 10.1093/jac/dku075
  • 78. John J.F., Falci D.R., Rigatto M.H., Oliveira R.D., Kremer T.G., Zavascki A.P. Severe infusion-related adverse events and renal failure in patients receiving high-dose intravenous polymyxin B. Antimicrob Agents Chemother. 2018;62(1). pii:e01617-17. DOI: 10.1128/AAC.01617-17
  • 79. Sandri A.M., Landersdorfer C.B., Jacob J., Boniatti M.M., Dalarosa M.G., Falci D.R., et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother. 2013;3:674-677. DOI: 10.1093/jac/dks437
  • 80. Nelson B.C., Eiras D.P., Gomez-Simmonds A., Loo A.S., Satlin M.J., Jenkins S.G., et al. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. Antimicrob Agents Chemother. 2015;11:7000-7006. DOI: 10.1128/AAC.00844-15
  • 81. Kwa A.L., Lim T.P., Low J.G., Hou J., Kurup A., Prince R.A., et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008;2:163-167. DOI: 10.1016/j.diagmicrobio.2007.08.008
  • 82. Abdelraouf K., Braggs K.H., Yin T., Truong L.D., Hu M., Tam V.H. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012;9:4625-4629. DOI: 10.1128/AAC.00280-12
  • 83. Polymyxin B [package insert]. Big Flats, NY: Xellia Pharmaceuticals; 2015.
  • 84. Baird J.S. Polymyxin B and haemofiltration in an adolescent with leukaemia. J Antimicrob Chemother. 2014;5:1434. DOI: 10.1093/jac/dkt522
  • 85. Rigatto M.H., Falci D.R., Lopes N.T., Zavascki A.P. Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B. Int J Antimicrob Agents. 2016;2:146150. DOI: 10.1016/j.ijantimicag.2015.11.007
  • 86. Spapen H.D., Honore P.M., Gregoire N., Gobin P., de Regt J., Martens G.A., et al. Convulsions and apnoea in a patient infected with New Delhi metallo-beta-lactamase-1 Escherichia coli treated with colistin. J Infect. 2011;6:468-470. DOI: 10.1016/j.jinf.2011.07.008
  • 87. Bode-Boger S.M., Schopp B., Troger U., Martens-Lobenhoffer J., Kalousis K., Mailänder P. Intravenous colistin in a patient with serious burns and borderline syndrome: the benefits of therapeutic drug monitoring. Int J Antimicrob Agents. 2013;4:357-360. DOI: 10.1016/j.ijantimicag.2013.06.009
  • 88. Gauthier T.P., Wolowich W.R., Reddy A., Cano E., Abbo L., Smith L.B. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother. 2012;5:2392-2396. DOI: 10.1128/AAC.00028-12
  • 89. Dubrovskaya Y., Prasad N., Lee Y., Esaian D., Figueroa D.A., Tam V.H. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015;6:19031907. DOI: 10.1093/jac/dkv014
  • 90. Pogue J.M., Lee J., Marchaim D., Yee V., Zhao J.J., Chopra T., et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;9:879-884. DOI: 10.1093/cid/cir611
  • 91. Temocin F., Erdinc S., Tulek N., Demirelli M., Bulut C., Ertem G. Incidence and risk factors for colistin-associated nephrotoxicity. Jpn J Infect Dis. 2015;4:318-320. DOI: 10.7883/yoken.JJID.2014.223
  • 92. Rigatto M.H., Behle T.F., Falci D.R., Freitas T., Lopes N.T., Nunes M., et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother. 2015;5:1552-1557. DOI: 10.1093/jac/dku561
  • 93. Petrosillo N., Giannella M., Antonelli M., Antonini M., Barsic B., Belancic L., et al. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother. 2014;2:851-858. DOI: 10.1128/AAC.00871-13
  • 94. Garnacho-Montero J., Amaya-Villar R., Gutierrez-Pizarraya A., Espejo-Gutiérrez de Tena E., Artero-González M.L., CorciaPalomo Y., et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy. 2013;3:225-231. DOI: 10.1159/000356004
  • 95. Gordon N.C., Png K., Wareham D.W. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;12:53165322. DOI: 10.1128/AAC.00922-10
  • 96. Rattanaumpawan P., Ungprasert P., Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect. 2011;2:187-190. DOI: 10.1016/j.jinf.2010.11.013
  • 97. Elias L.S., Konzen D., Krebs J.M., Zavascki A.P. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 2010;10:22312237. DOI: 10.1093/jac/dkq285
  • 98. Phe K., Shields R.K., Tverdek F.P., Aitken S.L., Guervil D.J., Lam W.M., et al. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. J Antimicrob Chemother. 2016;71:3585-3587. DOI: 10.1093/jac/dkw329
  • 99. Roberts K.D., Azad M.A., Wang J., Horne A.S., Thompson P.E., Nation R.L., et al. Antimicrobial activity and toxicity of the major lipopeptide components of polymyxin B and colistin: last-line antibiotics against multidrug-resistant Gram-negative bacteria. ACS Infect Dis. 2015;11:568-575. DOI: 10.1021/acsinfecdis.5b00085
  • 100. Tuon F.F., Aragao B.Z., Santos T.A., Gasparetto J., Cordova K., Abujamra M. Acute kidney injury in patients using amikacin in an era of carbapenem-resistant bacteria. Infect Dis (Lond). 2016;1112:869-871. DOI: 10.1080/23744235.2016.1205215
  • 101. Zavascki A.P., Manfro R.C., Maciel R.A., Falci D.R. Head and neck hyperpigmentation probably associated with Polymyxin B therapy. Ann Pharmacother. 2015;49(10):1171-1172. DOI: 10.1177/1060028015595643
  • 102. Yousef J.M., Chen G., Hill P.A., Nation R.L., Li J. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother. 2012;2:452-459. DOI: 10.1093/jac/dkr483
  • 103. Dalfino L., Puntillo F., Ondok M.J., Mosca A., Monno R., Coppolecchia S., et al. Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study. Clin Infect Dis. 2015;12:1771-1777. DOI: 10.1093/cid/civ717
  • 104. Sirijatuphat R., Limmahakhun S., Sirivatanauksorn V., Nation R.L., Li J., Thamlikitkul V. Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity. Antimicrob Agents Chemother. 2015;6:3224-3232. DOI: 10.1128/AAC.00280-15
  • 105. Zarjou A., Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol. 2011;6:999-1006. DOI: 10.1681/ASN.2010050484
  • 106. Rojas L.J., Salim M., Cober E., Richter S.S., Perez F., Salata R., et al. Colistin resistance in carbapenem-resistant Klebsiella pneumoniae: laboratory detection and impact on mortality. Clin Infect Dis. 2016;64(6):711-718. DOI: 10.1093/cid/ciw805
  • 107. Marchaim D., Chopra T., Pogue J.M., Perez F., Hujer A.M., Rudin S., et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother. 2011;2:593-599. DOI: 10.1128/AAC.01020-10
  • 108. Qureshi Z.A., Hittle L.E., O’Hara J.A., Rivera J.I., Syed A., Shields R.K., et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;9:1295-1303. DOI: 10.1093/cid/civ048
  • 109. Lenhard J.R., Thamlikitkul V., Silveira F.P., Garonzik S.M., Tao X., Forrest A., et al. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity. J Antimicrob Chemother. 2017;72(5):1415-1420. DOI: 10.1093/jac/dkx002
  • 110. Bulman Z.P., Ly N.S., Lenhard J.R., Holden P.N., Bulitta J.B., Tsuji B.T. Influence of rhlR and lasR on polymyxin pharmacodynamics in Pseudomonas aeruginosa and implications for quorum sensing inhibition with azithromycin. Antimicrob Agents Chemother. 2017;61(4). pii: e00096-16. DOI: 10.1128/AAC.00096-16
  • 111. Smith N.M., Bulman Z.P., Sieron A.O., Bulitta J.B., Holden P.N., Nation R.L., et al. Pharmacodynamics of dose-escalated ‘frontloading’ polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli. J Antimicrob Chemother. 2017;8:2297-2303. DOI: 10.1093/jac/dkx121
  • 112. Bulman Z.P., Chen L., Walsh T.J., Satlin M.J., Qian Y., Bulitta J.B., et al. Polymyxin combinations combat Escherichia coli harboring mcr-1 and blaNDM-5: preparation for a postantibiotic era. MBio. 2017;8(4). pii:e00540-17. DOI: 10.1128/mBio.00540-17
  • 113. Zhao M., Bulman Z.P., Lenhard J.R., Satlin M.J., Kreiswirth B.N., Walsh T.J., et al. Pharmacodynamics of colistin and fosfomycin: a ‘treasure trove’ combination combats KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2017;7:1985-1990. DOI: 10.1093/jac/dkx070
  • 114. Landersdorfer C.B., Ly N.S., Xu H., Tsuji B.T., Bulitta J.B. Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design. Antimicrob Agents Chemother. 2013;5:2343-2351. DOI: 10.1128/AAC.00092-13
  • 115. Lenhard J.R., Smith N.M., Bulman Z.P., Tao X., Thamlikitkul V., Shin B.S., et al. High dose ampicillin/sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollowfiber infection model. Antimicrob Agents Chemother. 2017;61(3). pii: e01268-16. DOI: 10.1128/AAC.01268-16
  • 116. Ly N.S., Bulitta J.B., Rao G.G., Landersdorfer C.B., Holden P.N., Forrest A., et al. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. J Antimicrob Chemother. 2015;5:1434-1442. DOI: 10.1093/jac/dku567
  • 117. Paul M., Carmeli Y., Durante-Mangoni E., Mouton J.W., Tacconelli E., Theuretzbacher U., et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014;9:2305-2309. DOI: 10.1093/jac/dku168
  • 118. Zusman O., Avni T., Leibovici L., Adler A., Friberg L., Stergiopoulou T., et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013;57(10):5104-5111. DOI: 10.1128/AAC.01230-13
  • 119. Zarkotou O, Pournaras S., Tselioti P., Dragoumanos V., Pitiriga V., Ranellou K., et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;12:1798-1803. DOI: 10.1111/j.1469-0691.2011.03514.x
  • 120. Qureshi Z.A., Paterson D.L., Potoski B.A., Kilayko M.C., Sandovsky G., Sordillo E., et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;4:2108-2113. DOI: 10.1128/AAC.06268-11
  • 121. Daikos G.L., Tsaousi S., Tzouvelekis L.S., Anyfantis I., Psichogiou M., Argyropoulou A., et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;4:2322-2328. DOI: 10.1128/AAC.02166-13
  • 122. Gutierrez-Gutierrez B., Salamanca E., de Cueto M., Hsueh P.R., Viale P., Paño-Pardo J.R., et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;7:726-734. DOI: 10.1016/S1473-3099(17)30228-1
  • 123. Tumbarello M., Viale P., Viscoli C., Trecarichi E.M., Tumietto F., Marchese A., et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;7:943-950. DOI: 10.1093/cid/cis588
  • 124. Tumbarello M., Trecarichi E.M., De Rosa F.G., Giannella M., Giacobbe D.R., Bassetti M., et al. Infections caused by KPCproducing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133-2143. DOI: 10.1093/jac/dkv086
  • 125. Paul M., Daikos G.L., Durante-Mangoni E., Yahav D., Carmeli Y., Benattar Y.D., et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391-400. DOI: 10.1016/S1473-3099(18)30099-9
  • 126. Durante-Mangoni E., Signoriello G., Andini R., Mattei A., De Cristoforo M., Murino P., et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;3:349-358. DOI: 10.1093/cid/cit253
  • 127. Sirijatuphat R., Thamlikitkul V. Preliminary study of Colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;9:5598-5601. DOI: 10.1128/AAC.02435-13
  • 128. Aydemir H., Akduman D., Piskin N., Comert F., Horuz E., Terzi A., et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013;6:12141222. DOI: 10.1017/S095026881200194X
  • 129. Furtado G.H., d’Azevedo P.A., Santos A.F., Gales A.C., Pignatari A.C., Medeiros E.A. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007;30:315319. DOI: 10.1016/j.ijantimicag.2007.05.017
  • 130. Falagas M.E., Rafailidis P.I., Ioannidou E., Alexiou V.G., Matthaiou D.K., Karageorgopoulos D.E., et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35:194-199. DOI: 10.1016/j.ijantimicag.2009.10.005
  • 131. Samonis G., Vardakas K.Z., Kofteridis D.P., Dimopoulou D., Andrianaki A.M., Chatzinikolaou I., et al. Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections. Infection. 2014;42:721-728. DOI: 10.1007/s15010-014-0635-z
  • 132. Rigatto M.H., Vieira F.J., Antochevis L.C., Behle T.F., Lopes N.T., Zavascki A.P. Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2015;59:6575-6580. DOI: 10.1128/AAC.00494-15
  • 133. Ribera A., Benavent E., Lora-Tamayo J., Tubau F., Pedrero S., Cabo X., et al. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus b-lactams. J Antimicrob Chemother. 2015;70:3357-3365. DOI: 10.1093/jac/dkv281
  • 134. Sorli L., Luque S., Segura C., Campillo N., Montero M., Esteve E., et al. Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa. BMC Infect Dis. 2017;17:11. DOI: 10.1186/s12879-016-2117-7
  • 135. Rattanaumpawan P., Lorsutthitham J., Ungprasert P., Angkasekwinai N., Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother. 2010;12:2645-2649. DOI: 10.1093/jac/dkq360
  • 136. Abdellatif S., Trifi A., Daly F., Mahjoub K., Nasri R., Ben Lakhal S. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care. 2016;6(1):26. DOI: 10.1186/s13613-016-0127-7
  • 137. Valachis A., Samonis G., Kofteridis D.P. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med. 2015;3:527533. DOI: 10.1097/CCM.0000000000000771
  • 138. Polat M., Kara S.S., Tapisiz A., Tezer H., Kalkan G., Dolgun A. Treatment of ventilator-associated pneumonia using intravenous colistin alone or in combination with inhaled colistin in critically ill children. Paediatr Drugs. 2015;4:323-330. DOI: 10.1007/s40272-015-0133-5
  • 139. Kalin G., Alp E., Coskun R., Demiraslan H., Gündogan K., Doganay M. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother. 2012;6:872-877. DOI: 10.1007/s10156012-0430-7
  • 140. Lu Q., Luo R., Bodin L., Yang J., Zahr N., Aubry A., et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology. 2012;6:1335-1347. DOI: 10.1097/ALN.0b013e31827515de
  • 141. Vardakas K.Z., Voulgaris G.L., Samonis G., Falagas M.E. Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018;51:1-9. DOI: 10.1016/j.ijantimicag.2017.05.016
  • 142. Jung S.Y., Lee S.H., Lee S.Y., Yang S., Noh H., Chung E.K., et al. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Crit Care. 2017;21:319. DOI: 10.1186/s13054-017-1916-6
  • 143. Jang J.Y., Kwon H.Y., Choi E.H., Lee W.Y., Shim H., Bae K.S. Efficacy and toxicity of high-dose nebulized colistin for critically ill surgical patients with ventilator-associated pneumonia caused by multidrug-resistant Acinetobacter baumannii. J Crit Care. 2017;40:251-256. DOI: 10.1016/j.jcrc.2017.04.004
  • 144. Klick J.M., du Moulin G.C., Hedley-Whyte J., Teres D., Bushnell L.S., Feingold D.S. Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients. J Clin Invest. 1975;3:514-519. DOI: 10.1172/JCI107957
  • 145. Feeley T.W., Du Moulin G.C., Hedley-Whyte J., Bushnell L.S., Gilbert J.P., Feingold D.S. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med. 1975;10:471-475. DOI: 10.1056/NEJM197509042931003
  • 146. Boisson M., Jacobs M., Gregoire N., Gobin P., Marchand S., Couet W., et al. Comparison of intrapulmonary and systemic pharmacokinetics of Colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014;12:7331-7339. DOI: 10.1128/AAC.03510-14
  • 147. Athanassa Z.E., Markantonis S.L., Fousteri M.Z., Myrianthefs P.M., Boutzouka E.G., Tsakris A., et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 2012;11:1779-1186. DOI: 10.1007/s00134-012-2628-7
  • 148. Huang J.X., Blaskovich M.A., Pelingon R., Ramu S., Kavanagh A., Elliott A.G., et al. Mucin binding reduces colistin antimicrobial activity. Antimicrob Agents Chemother. 2015;59(10):59255931. DOI: 10.1128/AAC.00808-15
  • 149. Wenzler E., Fraidenburg D.R., Scardina T., Danziger L.H. Inhaled antibiotics for Gram-negative respiratory infections. Clin Microbiol Rev. 2016;3:581-632. DOI: 10.1128/CMR.00101-15
  • 150. Rouby J.J., Bouhemad B., Monsel A., Brisson H., Arbelot C., Lu Q.; Nebulized Antibiotics Study Group. Aerosolized antibiotics for ventilator-associated pneumonia: lessons from experimental studies. Anesthesiology. 2012;6:1364-1380. DOI: 10.1097/ALN.0b013e3182755d7a
  • 151. Ehrmann S., Roche-Campo F., Sferrazza Papa G.F., Isabey D., Brochard L., Apiou-Sbirlea G.; REVA research network. Aerosol therapy during mechanical ventilation: an international survey. Intensive Care Med. 2013;6:1048-1056. DOI: 10.1007/s00134-013-2872-5
  • 152. Rello J., Sole-Lleonart C., Rouby J.J., Chastre J., Blot S., Poulakou G., et al. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. 2017;23(9):629-639. DOI: 10.1016/j.cmi.2017.04.011
  • 153. Tunkel A.R., Hasbun R., Bhimraj A., Byers K., Kaplan S.L., Scheld W.M., et al. 2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis. 2017;64(6):e34-e65. DOI: 10.1093/cid/ciw861
  • 154. Kim B.N., Peleg A.Y., Lodise T.P., Lipman J., Li J., Nation R., et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis. 2009;4:245-255. DOI: 10.1016/S1473-3099(09)70055-6
  • 155. Karaiskos I., Giamarellou H. Multidrug-resistant and extensively drug-resistant gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;10:1351-1370. DOI: 10.1517/14656566.2014.914172
  • 156. Markantonis S.L., Markou N., Fousteri M., Sakellaridis N., Karatzas S., Alamanos I., et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother. 2009;11:4907-4910. DOI: 10.1128/AAC.00345-09
  • 157. Antachopoulos C., Karvanen M., Iosifidis E., Jansson B., Plachouras D., Cars O., et al. Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob Agents Chemother. 2010;9:3985-3987. DOI: 10.1128/AAC.01799-09
  • 158. Imberti R., Cusato M., Accetta G., Marinò V., Procaccio F., Del Gaudio A., et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. Antimicrob Agents Chemother. 2012;8:4416-4421. DOI: 10.1128/AAC.00231-12
  • 159. Falagas M.E., Bliziotis I.A., Tam V.H. Intraventricular or intrathecal use of polymyxins in patients with gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents. 2007;1:9-25. DOI: 10.1016/j.ijantimicag.2006.08.024
  • 160. Karaiskos I., Galani L., Baziaka F., Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents. 2013;6:499-508. DOI: 10.1016/j.ijantimicag.2013.02.006
  • 161. Bargiacchi O., De Rosa F.G. Intrathecal or intraventricular colistin: a review. Infez Med. 2016;1:3-11. PMID: 27031890
  • 162. Piparsania S., Rajput N., Bhatambare G. Intraventricular polymyxin B for the treatment of neonatal meningo-ventriculitis caused by multi-resistant Acinetobacter baumannii – case report and review of literature. Turk J Pediatr. 2012;5:548-554.
  • 163. Hoenigl M., Drescher M., Feierl G., Valentin T., Zarfel G., Seeber K., et al. Successful management of nosocomial ventriculitis and meningitis caused by extensively drug-resistant Acinetobacter baumannii in Austria. Can J Infect Dis Med Microbiol. 2013;3:e88-90. DOI: 10.1155/2013/613865
  • 164. Remes F., Tomas R., Jindrak V., Vanis V., Setlik M. Intraventricular and lumbar intrathecal administration of antibiotics in postneurosurgical patients with meningitis and/or ventriculitis in a serious clinical state. J Neurosurg. 2013;6:1596-1602. DOI: 10.3171/2013.6.JNS122126
  • 165. Karagoz G., Kadanali A., Dede B., Sahin O.T., Comoglu S., Altug S., et al. Extensively drug-resistant Pseudomonas aeruginosa ventriculitis and meningitis treated with intrathecal colistin. Int J Antimicrob Agents. 2014;1:93-94. DOI: 10.1016/j.ijantimicag.2013.09.007
  • 166. Bargiacchi O., Rossati A., Car P., Brustia D., Brondolo R., Rosa F., et al. Intrathecal/intraventricular colistin in external ventricular device-related infections by multi-drug resistant gram negative bacteria: case reports and review. Infection. 2014;5:801-809. DOI: 10.1007/s15010-014-0618-0
  • 167. Santos A.S., Iraneta A., Matos M., Brito M.J. Intraventricular colistin in gram-negative ventriculoperitoneal shunt infection in two pediatric patients. Acta Neurochir (Wien). 2015;12:22192220. DOI: 10.1007/s00701-015-2588-0
  • 168. Schiaroli E., Pasticci M.B., Cassetta M.I., Fallani S., Castrioto C., Pirro M., et al. Management of meningitis caused by multi drug-resistant Acinetobacter baumannii: clinical, microbiological and pharmacokinetic results in a patient treated with colistin methanesulfonate. Mediterr J Hematol Infect Dis. 2015;1:e2015055. DOI: 10.4084/MJHID.2015.055
  • 169. Shofty B., Neuberger A., Naffaa M.E., Binawi T., Babitch T., Rappaport Z.H., et al. Intrathecal or intraventricular therapy for post-neurosurgical gram-negative meningitis: matched cohort study. Clin Microbiol Infect. 2016;1:66-70. DOI: 10.1016/j.cmi.2015.09.023
  • 170. Shrestha G.S., Tamang S., Paneru H.R., Shrestha P.S., Keyal N., Acharya S.P., et al. Colistin and tigecycline for management of external ventricular device-related ventriculitis due to multidrugresistant Acinetobacter baumannii. J Neurosci Rural Pract. 2016;3:450-452. DOI: 10.4103/0976-3147.176194
  • 171. De Bonis P., Lofrese G., Scoppettuolo G., Spanu T., Cultrera R., Labonia M., et al. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter baumannii meningitis. Eur J Neurol. 2016;1:68-75. DOI: 10.1111/ene.12789
  • 172. Souhail D., Bouchra B., Belarj B., Laila R., Mohammed F., Nassirou O.M., et al. Place of colistin-rifampicin association in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: a case study. Case Rep Infect Dis. 2016;2016:8794696. DOI: 10.1155/2016/8794696
  • 173. Fotakopoulos G., Makris D., Chatzi M., Tsimitrea E., Zakynthinos E., Fountas K. Outcomes in meningitis/ventriculitis treated with intravenous or intraventricular plus intravenous colistin. Acta Neurochir (Wien). 2016;3:603-610; discussion 610. DOI: 10.1007/s00701-016-2702-y
  • 174. Inamasu J., Ishikawa K., Oheda M., Nakae S., Hirose Y., Yoshida S. Intrathecal administration of colistin for meningitis due to New Delhi metallo-beta-lactamase 1(NDM-1)-producing Klebsiella pneumoniae. J Infect Chemother. 2016;3:184-186. DOI: 10.1016/j.jiac.2015.10.007
  • 175. Ceylan B., Arslan F., Sipahi O.R., Sunbul M., Ormen B., Hakyemez I.N., et al. Variables determining mortality in patients with Acinetobacter baumannii meningitis/ventriculitis treated with intrathecal colistin. Clin Neurol Neurosurg. 2017;153:4349. DOI: 10.1016/j.clineuro.2016.12.006
  • 176. Singh R.K., Bhoi S.K., Kalita J., Misra U.K. Multidrug-resistant Acinetobacter meningitis treated by intrathecal colistin. Ann Indian Acad Neurol. 2017;1:74-75. DOI: 10.4103/09722327.199908.
  • 177. Kuzmenkov A.Yu, Trushin I.V., Avramenko A.A., Edelstein M.V., Dekhnich A.V., Kozlov R.S. AMRmap: an online platform for monitoring antibiotic resistance. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(2):84-90. Russian.
  • 178. Sukhorukova M.V., Edelstein M.V., Skleenova E.Yu., Ivanchik N.V., Shajdullina E.R., Azyzov I.S., et al. Antimicrobial resistance of nosocomial Enterobacterales isolates in Russia: results of multicenter epidemiological study “MARATHON 2015–2016”. Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(2):147-159. Russian. DOI: 10.36488/cmac.2019.2.147-159
  • 179. Ageevets V., Lazareva I., Mrugova T., Gostev V., Lobzin Y., Sidorenko S. IncX4 plasmids harbouring mcr-1 genes: Further dissemination. J Glob Antimicrob Resist. 2019;18:166-167. DOI: 10.1016/j.jgar.2019.07.002
  • 180. Azizov I, Sheck E, Sukhorukova M, Edelstein M V. Plasmidmediated resistance to colistin in clinical isolates of Klebsiella spp. and Escherichia coli: results of large retrospective surveillance in Russia. In: European Congeress of Clinical Microbiology and Infection Diseases. 2019. #P1413. DOI: 10.13140/RG.2.2.34812.59527
  • 181. Edelstein M.V., Shek E.A., Sukhorukova M.V., Skleenova E.Yu., Ivanchik N.V., Shajdullina E.R., et al. Antimicrobial resistance, carbapenemase production, and genotypes of nosocomial Pseudomonas aeruginosa isolates in Russia: results of multicenter epidemiological study “MARATHON 2015–2016”. Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(2):160-170. Russian. DOI: 10.36488/cmac.2019.2.160-170
  • 182. Shek E.A., Sukhorukova M.V., Edelstein M.V., Skleenova E.Yu., Ivanchik N.V., Shajdullina E.R., et al. Antimicrobial resistance, carbapenemase production, and genotypes of nosocomial Acinetobacter spp. isolates in Russia: results of multicenter epidemiological study” MARATHON 2015–2016”. Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(2):171-180. Russian. DOI: 10.36488/cmac.2019.2.171-180
  • 183. Castanheira M., Griffin M., Lalitagauri A., Deshpande. M., Jones R., Flamm R. Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY antimicrobial surveillance program in 2014 and 2015. Antimicrob Agents Chemother. 2016;60:5623–5624. doi:10.1128/AAC.01267-16
Views
0 Abstract
0 PDF
0 Crossref citations
Shared